CTEX CPAP versus Conventional CPAP in Managing COVID-19 related Respiratory Failure: Experience from a Hospital
DOI:
https://doi.org/10.31344/ijhhs.v9i1.770Keywords:
COVID-19, continuous positive airway pressure, non-invasive ventilation, oxygen saturation, respiratory failureAbstract
Background: Continuous positive airway pressure (CPAP) is the preferred form of noninvasive ventilatory support in the management of type 1 respiratory failure in COVID-19 patients with a pure failure of oxygenation only. Limiting the inherent disadvantages, the improved and enhanced CTEX CPAP device may benefit the patients. Objective: To evaluate the clinical effectiveness of a new novel continuous positive airway pressure (CPAP) device CTEX in managing COVID-19-associated type 1 respiratory failure. Methods: This open-label, double cross-over, non-inferiority trial was conducted among COVID-19-positive patients with respiratory failure who required oxygen supplementation and were admitted to the intensive care unit (ICU), under Department of Anaesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University (BSMMU) Hospital, Dhaka, Bangladesh, between August 2020 and January 2021. A total of 39 patients with confirmed positive COVID-19 receiving standard CPAP (10-16cm of water) and entrained oxygen (2-15 L/ minute) and having peripheral oxygen saturations (SpO2) <94% were included in this study. Patients were given standard CPAP for 1 hour followed by CTEX CPAP for 12 hours and then switched back to standard CPAP for 1 hour. The primary outcome measure was the evaluation of oxygen saturation (SpO2) over 12 hours, which was measured hourly across 11 hours starting at T0 for the initial value and ending at T11 for the final value. Results: The mean age of the patients was 60.25±11.70 years; male to female ratio was 3.3:1. Most of the patients 21(54%) had SpO2 of 80-90% on admission. The average respiratory rate was 28.15±1.42 breaths per minute. SpO2 before and after applying CTEX CPAP were observed 88% (ranged between 81% and 94%) and 95% (ranged between 91% and 100%) respectively. There was a significant improvement in SpO2 and the value was increased over time and then plateaued. Conclusion: CTEX CPAP device was found to be significantly better at oxygenation for the treatment of COVID-19 patients with type 1 respiratory failure.
International Journal of Human and Health Sciences Vol. 09 No. 01 Jan’25 Page: 42-47
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 AKM Akhtaruzzaman, Md Mostafa Kamal, Dilip Kumar Bhowmick, Md Shafiqul Islam, Selim Musa Mithu
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the International Journal of Human and Health Sciences agree to the following terms that:
- Authors retain copyright and grant International Journal of Human and Health Sciences the right of first publication of the work.
Articles in International Journal of Human and Health Sciences are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.
